Research Article

Analysis of Nucleotide Variations in Genes of Iron Management in Patients of Parkinson's Disease and Other Movement Disorders

Table 1

Allelic frequencies of the sequence variations identified in FTL, FTH, FTMT, CP, IRP2, HPX, and HAMP genes in PD patients and controls.

GenePDCNTDNA variationGene positionAFAFAF
PDCNTDB

FTL252180c+163T>Cex. 219.05% (96/504)25% (90/360)52% (1)
c+522C>Tex. 40.20% (1/504)none
c+398A>C (H133P)ex. 40.20% (1/504)none
c−129delCIRE-L0.20% (1/504)none
c−37T>C UTR0.20% (1/504)none
IVS2+50C>Tint. 20.40% (2/504)none
IVS2+60T>Gint. 20.40% (2/504)0.56% (2/360)
IVS2+66G>Cint. 20.20% (1/504)none

FTH252180c+161A>G (K54R)ex. 2none0.56% (2/360)
IVS2+29 ins GTCATAG2int.23.57% (18/504)4.44% (16/360)
IVS2+23 G>Aint.20.20% (1/504)none

FTMT332342c+134C>A (P45H)ex.1.1.05% (7/664)2.49% (17/684)
c+273C>T (S91S)ex.10.15% (1/664)none
c+506A>T (N169I)ex.1none0.15% (1/684)
c+554G>A (G185D) rs35482405ex.10.15% (1/664)none1.5% (2)
c+646G>C (V216L)ex.10.15% (1/664)0.29% (2/684)
c+667G>T (A223S)ex.10.15% (1/664)0.29% (2/684)
c+745C>T UTR0.15% (1/664)none

CP103nonec+484A>T (T162S)ex. 30.49% (1/206)
c+788A>G (N263S)ex. 50.49% (1/206)
c+1430C>T (P477L) rs35331711ex. 80.49% (1/206)1.3% (2)
c+1632A>T (D544E) rs701753ex. 94.85% (10/206)7.5% (1)
c+1652C>T (T551I)3 rs61733458ex. 94.37% (9/206)nd
c+1950A>C (G650G) rs1053709ex. 113.88% (8/206)5.1% (1)
c+2446G>A (V816L)ex. 140.49% (1/206)
c+2522C>G (T841R)3 rs56033670ex. 140.97% (2/206)nd
c+2571C>T (Y857Y)ex. 150.49% (1/206)
c+2793 A>G (L931L) rs34987997ex. 160.49% (1/206)2.2% (3)
c+2991T>C (H997H) rs34394958ex. 172.91% (6/206)7.9% (3)
IVS1+41G>A rs3736282int. 16.31% (13/206)11.4% (3)
IVS2+20C>T rs17847023int. 24.85% (10/206)10.9% (3)
IVS4−14C>T rs34067682int. 42.43% (5/206)6.5% (3)
IVS5−51A>G rs34003547int. 54.37% (9/206)2.3% (3)
IVS7−47G>Aint. 70.97% (2/206)
IVS9−38T>C rs6799507int. 91.46 % (3/206)0.8% (1)
IVS10+62T>C rs35149808int. 100.49% (1/206)0.0% (3)
IVS10+113C>T rs35516209int. 104.37% (9/206)4.5% (3)
IVS14+17G>A rs35593818int. 143.88% (8/206)6.2% (3)
IVS12−15delG rs34861155int. 1217.96% (37/206)36.4% (3)
IVS15−12T>C rs16861582int. 1515.05% (31/206)32.5% (1). 20.8% (4)
IVS17−78T>Cint. 170.49% (1/206)
c+3335C>T rs34228141 UTR2.43% (5/206)

IRP250nonec+2616C>T (A872A) rs13180ex. 2121% (21/100)35% (1)
c−89C>T4 rs954144 UTR28% (28/100)44% (1)
IVS4−56G>Cint. 42% (2/100)
IVS5+22A>C rs2938672int. 51% (1/100)0% (1)
IVS5+73delC rs11372841int. 51% (1/100)nd
IVS7+19A>G rs3817092int. 710% (10/100)16.1% (1)
IVS12+50G>A rs9788758int. 122% (2/100)nd

HPX10394c+1017C>T (S339S)ex. 9 None0.5% (1/188)
IVS1+24C>T rs35862450int. 113.1% (27/206)19.7% (37/188)
IVS1−32T>Aint. 11%(2/206) None26.4% (5)
IVS1−41C>Tint. 1None0.5% (1/188)
IVS8−26A>Gint. 8None0.5% (1/188)

HAMP5050c−72C>T1.0% (1/100)None
c+55G>A (A19T)ex 11.0% (1/100)None

Genomic DNA from PD patients and controls was PCR amplified and scanned by DHPLC. PD: Parkinson’s disease, CNT: controls, AF: allelic frequency, DB: database.
FTL: ferritin light chain (NM_000146.3), FTH: ferritin heavy chain (NM_002032.2), FTMT: mitochondrial ferritin (NM_026286.2), CP: ceruloplasmin (NM_000096.3), IRP2: iron regulatory protein 2 (NM_004136.2), HPX: hemopexin (NM_000613.2), HAMP: hepcidin (NM_021175.2), ex: exon, int: intron, (1) HapMap-CEU, (2) AGI ASP POPULATION, (3) JAR CEPH-PANEL, (4) AFD EUR PANEL, (5) pilot1.CEU.